Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Healius Limited ( (AU:HLS) ) is now available.
Healius Limited has announced the appointment of Bruce Robinson as a director of the company, effective 2 February 2026. According to the initial director’s interest notice lodged with the ASX, Robinson currently holds no relevant interests in Healius securities and has no interests in any related contracts, indicating that he joins the board without an existing equity stake or contractual ties that could affect his independence.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.95 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian-listed healthcare company operating in the medical services sector. It provides diagnostic and related healthcare services across Australia, with its securities traded on the ASX under standard corporate governance and disclosure requirements.
YTD Price Performance: -0.55%
Average Trading Volume: 1,992,805
Technical Sentiment Signal: Sell
Current Market Cap: A$653.5M
See more insights into HLS stock on TipRanks’ Stock Analysis page.